Cantor Fitzgerald Begins Coverage on Pharvaris (NASDAQ:PHVS)

Cantor Fitzgerald began coverage on shares of Pharvaris (NASDAQ:PHVS) in a research report sent to investors on Tuesday, MarketBeat reports. The firm issued an overweight rating and a $28.00 price objective on the stock.

Separately, JMP Securities increased their price objective on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, January 31st.

Pharvaris Stock Up 1.2 %

Shares of PHVS opened at $17.27 on Tuesday. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50. The stock has a market cap of $903.05 million, a PE ratio of -6.17 and a beta of -2.84. The business’s 50-day moving average price is $14.96 and its 200-day moving average price is $18.08.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.06. Analysts expect that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Institutional investors have recently modified their holdings of the company. Palumbo Wealth Management LLC boosted its stake in Pharvaris by 38.0% in the first quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company’s stock worth $221,000 after buying an additional 3,881 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Pharvaris by 30.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company’s stock valued at $1,222,000 after purchasing an additional 14,838 shares in the last quarter. Woodline Partners LP bought a new position in shares of Pharvaris during the 4th quarter valued at $853,000. Soleus Capital Management L.P. grew its holdings in shares of Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after purchasing an additional 216,483 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Pharvaris in the 4th quarter worth $152,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.